# Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease

> **NCT04569825** · EARLY_PHASE1 · UNKNOWN · sponsor: **University Of Anbar** · enrollment: 250 (estimated)

## Conditions studied

- Clinical Trial

## Interventions

- **DRUG:** Ophtamesone

## Key facts

- **NCT ID:** NCT04569825
- **Lead sponsor:** University Of Anbar
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-10-15
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04569825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04569825, "Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04569825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*